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An AssessMent of the econoMic iMPAct of the ADoPtion of A new 
MechAnicAl fixAtion Device Along with A new skirteD intrA-
PeritoneAl onlAy Mesh (iPoM) on hosPitAl costs of oPen ventrAl 
herniA rePAir surgeries
Panish J.M.1, Chekan E.2, Roy S.1
1Ethicon, Somerville, NJ, USA, 2Johnson & Johsnon (Ethicon), Cincinnati, OH, USA
Objectives: Demonstrating economic value of new products is important for hos-
pitals adoption. The combination of two devices: ETHICON SECURESTRAP® Open 
Absorbable Strap Fixation Device and ETHICON PHYSIOMESH™ Open Flexible 
Composite Mesh Device, offers a standardized approach to open IPOM repair 
of ventral hernia. This analysis assesses the potential economic value of using 
these devices when compared with other meshes and a hand-sutured fixation 
approach. MethOds: An economic model was developed to evaluate the budget 
impact to hospitals adopting ETHICON SECURESTRAP™ Open Fixation Device with 
ETHICON PHYSIOMESH™ Open in ventral hernia repair. A 1- to 3-year time horizon 
was included in the Excel-based model. An increasing utilization rate for ETHICON 
SECURESTRAP™ Open (20% - 60%), and ETHICON PHYSIOMESH™ Open (10% - 30%) 
was assumed over 3-year horizon. Costs of the mechanical fixation device, suture 
supplies, mesh, OR time, anesthesia time, and potentially avoided surgical site infec-
tions were considered. The differences in total costs were calculated. Results: 
Based on the model inputs, a 3-year total potential saving of $240,650 was estimated 
for 100 annual open ventral hernia surgeries using ETHICON SECURESTRAP™ Open 
Fixation Device versus suture of various meshes. Over three years, although the use 
of ETHICON SECURESTRAP™ Open Fixation Device added $54,600 in supplies costs, 
this was completely offset by potential savings in OR time costs ($167,520), potential 
reduction in avoided surgical site infection or seroma costs due to shorter operat-
ing room time ($126,903), and potential reduction in anesthesia costs ($17,189). 
Similarly, a savings of $40,108 was expected in the very first year. cOnclusiOns: 
This analysis represents the first economic evaluation of ETHICON SECURESTRAP™ 
Open Fixation Device with ETHICON PHYSIOMESH™ Open in open ventral hernia 
surgery. Adoption of the two devices would likely result in savings for hospitals, 
driven by shorter procedure time and related expected clinical benefits.
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cost AnAlyses of lutonix® 035 DcB PtA cAtheters for the treAtMent 
of feMoroPoPliteAl Artery stenosis: A u.s. hosPitAl PersPective
Delatore P.1, Hollmann S.2, Ferko N.2
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Objectives: Peripheral artery disease affects 8-10 million U.S. adults and 50% 
involve femoropopliteal arteries. A novel treatment, the Lutonix®035 Drug Coated 
Balloon PTA catheter (DCB) is indicated for percutaneous transluminal angioplasty 
(PTA), after pre-dilatation, of de novo or restenotic lesions up to 150mm in length 
in native superficial femoral or popliteal arteries with reference vessel diameters 
of 4-6mm. These analyses estimated the potential cost impact of DCBs vs. current 
care. MethOds: These economic modeled analyses compared total costs with vs. 
without DCBs over one year in a real-world scenario treatment mix for femoro-
popliteal PAD; these analyses were not based upon head-to-head clinical compari-
sons. For the inpatient hospital perspective, DCBs were compared with PTA, bare 
metal stents (BMS), drug-eluting stents (DES), covered stents (CS), and atherectomy. 
For the outpatient perspective, DCBs plus short spot stents were compared with 
BMS, DES, CS, and atherectomy. Equal distribution of treatment options in a world 
with vs. without DCBs was assumed. Consumable device-related costs (based upon 
published costs, where available) associated with initial procedures and repeat 
procedures (i.e., estimated target lesion revascularizations (TLRs)) were included. 
Average device utilization was informed by RCTs and TLR risk was derived from 
a network meta-analysis. Alternative analyses, including incremental reimburse-
ment for DCBs, or different utilization/comparator assumptions, were also evalu-
ated. Results: When including DCBs into the mix of treatments (1,000 patients) 
one-year cost-savings were estimated to be $74,735 and $104,688 for inpatient and 
outpatient hospital perspectives, respectively. Additionally, DCBs were predicted 
to be cost-saving in the majority of analyses vs. individual therapies (e.g., DCB 
vs. CS: -$2,202 to -$2,967 per patient). Alternative analyses assuming incremental 
reimbursement predicted that DCBs could provide even greater cost-savings under 
a Medicare payment scenario. cOnclusiOns: These analyses suggest that DCBs 
may provide cost-savings from a hospital perspective when considering the full 
range of comparators.
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iMPAct of sAMPle collection MethoD for egfr MutAtion testing: 
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Objectives: Sufficient tissue sample is not always available for EGFR mutation 
testing to direct treatment with tyrosine kinase inhibitors in NSCLC patients. We 
compared the impact of using the FDA-approved cobas® EGFR Mutation Test alone 
versus using blood-based cobas® EGFR Mutation Test as an alternative test for 
patients without adequate tissue sample in NSCLC patient treatment decision-
making in the US. MethOds: A decision-tree model was developed to compare 
testing methodologies and resulting treatment pathways in a hypothetical NSCLC 
US population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16%. Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures, average patient survival time, and budget impact. The combination of tis-
sue and blood-based testing were examined in four different scenarios. Results: 
Blood-based EGFR mutation testing is a more accessible method for identifying 
EGFR mutation status for patients without a tissue sample. More patients received 
Objectives: Mastectomy and lumpectomy procedures are often carried out using 
electrocautery; however, clinical evidence has demonstrated that the use of ultra-
sonic energy may reduce blood loss, seroma formation, wound infection, flap necro-
sis, hematoma, prolonged axillary drainage and length of stay. In the Canadian 
healthcare environment hospitals are faced with increasingly restrictive budgets, 
creating a critical need to demonstrate the cost-effectiveness of new technolo-
gies. This study was conducted to determine whether the reduction in complica-
tions associated with the use of ultrasonic energy in mastectomy and lumpectomy 
procedures offsets the increased device costs in a Canadian hospital. MethOds: 
We examined the budget impact of replacing electrocautery devices with ultra-
sonic energy in a hospital that performs 100 lumpectomies and 100 mastectomies 
annually. The model incorporates the costs associated with surgery, length of stay 
(taking into account facility and staff costs) and postoperative complications. The 
cost data was obtained from the Ontario Case Costing Initiative and case costing 
from a large Canadian hospital. Patient outcomes data was obtained from pooling 
published, peer reviewed literature after completing a comprehensive literature 
review. A multivariate sensitivity analysis was completed to ensure scientific rig-
our. Results: The use of electrocautery in mastectomy and lumpectomy proce-
dures is associated with lower device costs when compared to the use of ultrasonic 
energy devices. However, mastectomies and lumpectomies completed with ultra-
sonic energy devices demonstrate reduced operating time, a reduction in length of 
stay and a reduction in post-operative complications which offsets the increased 
device costs. The model establishes that replacing electrocautery with ultrasonic 
devices in a Canadian hospital performing 100 mastectomies and 100 lumpectomies 
annually would allow for a potential cost avoidance of $171,966. cOnclusiOns: In 
a Canadian hospital, the use of ultrasonic energy in mastectomy and lumpectomy 
procedures provides a cost savings when compared to the use of electrocautery.
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BuDget iMPAct of PercutAneous enDovAsculAr ABDoMinAl AortA 
AneurysM (AAA) rePAir coMPAreD to stAnDArD enDovAsculAr rePAir 
in cAnADiAn hosPitAls
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Objectives: Canadian hospitals spend an estimated $111 million annually on elec-
tive AAA repair. Percutaneous endovascular abdominal aortic repair approach (PEVAR) 
is a new minimally invasive technique that avoids surgical cut down associated with 
standard endovascular AAA repair (EVAR). Innovations in access devices and low pro-
file stent grafts have enabled the PEVAR approach. According to recent studies, PEVAR 
may offer substantial efficiency benefits as well as a reduction in post-operative 
complications and patient pain. The objective of our study was to evaluate the budget 
impact to a hospital of changing the technique for AAA repair from the EVAR approach 
to the PEVAR approach. MethOds: We examined the budget impact of replacing 
the EVAR approach with the PEVAR approach in a Canadian hospital that performs 
100 endovascular AAA repairs annually. The model incorporates the costs associated 
with surgery, length of stay and postoperative complications occurring within 30 
days. The cost data used in the model was obtained from peer reviewed literature, 
the Ontario Case Costing Initiative and case costing from a large Canadian hospital. 
Patient outcomes data was obtained from pooling published prospective studies after 
completing a comprehensive literature review. A multivariate sensitivity analysis was 
completed. Results: The use of PEVAR in AAA repair is associated with increased 
access device costs when compared to the EVAR approach. However, AAA repair com-
pleted with the PEVAR approach demonstrate reduced operating time, a reduction 
in length of stay and time in the recovery room and a reduction in post-operative 
complications which offset the increased device costs. The model establishes that 
switching to the PEVAR approach in a Canadian hospital performing 100 AAA repairs 
annually would result in a potential cost avoidance of $245,130. cOnclusiOns: A 
change in AAA repair technique from EVAR to PEVAR can be a cost-effective solution 
for Canadian hospitals.
PMD20
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AnAlysis of heAlth resource utilizAtion (hru) in the uniteD stAtes
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Objectives: Diabetes (DM) is prevalent among hospitalized patients making insulin 
administration a regular practice in acute care. Variability in the method of adminis-
tration leaves room for optimization. A budget impact model was created to evaluate 
the impact of passive SPN on healthcare worker safety and HRU in the acute care 
setting. MethOds: Model inputs include fixed assumptions of insulin waste and 
cost, needle stick injury (NSI) rates from safety syringe (SS) and SPN, nursing time, 
and supply costs. Inputs were obtained from the literature and real-world pilot 
studies. The model compares 4 scenarios using insulin vial with SS versus using 
insulin pens with SPN: 1) SS+10mL vial patient supply, 2) SS+10mL vial floor stock, 
3) SS+3mL vial patient supply, 4) SS+3mL vial floor stock. Results: Using insulin 
pens with SPN reduced NSIs, decreased nursing time, and increased injection sup-
ply cost. Insulin consumption varies based on the scenario and affects economic 
outcomes. When applying real-world data from a 52-bed pilot study to each scenario, 
annual cost savings (+) or expenditures (-) from switching to SPN are as follows: 
1) +$27,622, 2) -$5,951, 3) +$18,730, 4) -$14,485. cOnclusiOns: The cost of NSI 
contributes significantly to total HRU in the acute care setting in the US. Benefits 
of switching to SPN include reducing NSIs and decreasing nursing time needed to 
prepare an insulin injection. For individual patient supply scenarios (scenarios 1 
and 3), switching to SPN can reduce both NSIs and total cost to the institution. It 
is important to note that although the real-world pilot study results above are not 
generalizable, the model is adaptable to any institution based on number of beds 
and yearly insulin consumption. NSI rates may be underestimated, and in these 
cases, adoption of SPN may have a positive budget impact while improving health 
care worker safety.
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among patients receiving different HA treatments in a commercially-insured cohort 
of patients with knee OA. MethOds: Retrospective analyses using IMS Health’s 
PharMetrics Plus Health Plan Claims Database were conducted by identifying knee 
OA patients with claims indicating initiation of HA treatment at an index date 
during the selection period (2007-2010). Patients were required to be continuously 
enrolled in the health claims database from 12-months pre-index to 36-months 
post. A generalized linear model (GLM) with a gamma distribution and log-link 
function was used to model aggregate patient-based changes in disease-specific 
costs. A Cox proportional hazards model (PHM) was used to model risk of TKR. Both 
multivariate models included covariates such as age, gender, comorbidities, and 
pre-index healthcare costs. Results: 50,389 patients with HA treatment for knee 
OA were identified. 18,217 (36.2%) patients received Supartz/Hyalgan (shared HCPCS 
code), 20,518 (40.7%) Synvisc, 6,263 (12.4%) Euflexxa, and 5,391 (10.7%) Orthovisc. 
Synvisc and Orthovisc patients showed more disease-specific costs compared to 
Supartz/Hyalgan (8.9% (p< 0.0001) and 6.8% (p= 0.0048) increase respectively). This 
implies that if users of Synvisc and Orthovisc with average disease-specific costs 
of $14,959 and $14,224 switch to Supartz/Hyalgan, they can save $1,223 and $906 
over 3 years respectively. Hazard ratios showed a significantly higher risk of TKR 
for patients receiving Synvisc compared to Supartz/Hyalgan (6.9% increase in haz-
ard (p= 0.0009)). Patients treated with Supartz/Hyalgan, Euflexxa and Orthovisc had 
longer delays of TKR. cOnclusiOns: Multivariate statistical modeling showed that 
Supartz/Hyalgan represents a cost-effective alternative for providers. Both HAs 
reduce disease-specific costs and delay TKR when compared to other products.
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econoMic vAlue of Preventing centrAl venous cAtheter sePsis 
infections with eArly cAnnulAton Arteriovenous grAfts (ecAvgs) 
coMPAreD to non-ecAvgs
Mohr B.A., Trovillion P.J.
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Objectives: Approximately 80% of US hemodialysis patients initiate dialysis with 
a central venous catheter (CVC) despite their high incidence of infections compared 
to other vascular access modalities (USRDS 2011). Early cannulation arteriovenous 
grafts (ecAVGs) can be cannulated within 24 hours of implantation thus minimizing 
the dependency on CVCs compared to non-ecAVGs. We compare CVC sepsis costs for 
patients implanted with ecAVGs to those with non-ecAVGs. MethOds: An economic 
model was estimated using the GORE® ACUSEAL Vascular Graft (GAVG) Clinical Study 
(Clinicaltrials.gov NCT01173718), clinical literature, and publicly available cost sources. 
The GAVG study was a prospective, multi-center, single-arm study to establish the 
safety and efficacy of the GAVG for use in hemodialysis access. The study collected 
data on the first three consecutive hemodialysis sessions, which is a surrogate end-
point for time to potential CVC removal. The median days to potential CVC removal 
was 15.5 compared to an average of 34 days for non-ecAVGs from Quinn (2009) and 
Shingarev et al. (2011). CVC sepsis rates of 2.32 per patient-year were obtained from 
the US Renal Data System (2011). The CVC sepsis hospitalization cost was calculated 
as $27,088 (2014 dollars) from HCUP NIS (2010). Results: Assuming 100 patients in 
each group, the ecAVG group was estimated to have 9.9 CVC sepsis episodes com-
pared to 21.6 in the non-ecAVG group, with estimated sepsis hospitalization costs 
of $268,171 versus $585,100, respectively, due to the extended time on the CVC. The 
ecAVG potentially reduces CVC sepsis episodes by 11.7 since it reduces the number 
of catheter-dependent days by 18.5 compared to the non-ecAVG. On a per patient 
basis, the estimated average CVC sepsis costs in the ecAVG group were $2,682/patient 
versus $5,851/patient in the non-ecAVG group, resulting in a cost savings of $3,189/
patient. cOnclusiOns: It is estimated ecAVGs reduce overall CVC sepsis costs com-
pared to non-ecAVGs due to fewer CVC-dependent days.
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econoMic iMPAct of oPen MechAnicAl stAPling vs. MAnuAl suturing 
in ileocolic AnAstoMosis in MexicAn PuBlic heAlthcAre institutions
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Objectives: Manual suturing is currently used to perform ileocolic anastomosis in 
colorectal surgery. Because of its documented post-surgical complications shown 
in literature (anastomotic leaks and reoperations), alternative techniques such as 
mechanical stapling might yield clinical and economic benefits for hospitals. The 
objective of this study was to estimate the economic impact derived from the use of 
mechanical stapling and handsewn techniques in open ileocolic anastomoses from 
a Mexican public hospital perspective (IMSS). MethOds: An Excel-based decision 
tree model was used to compare clinical and economic outcomes of both anasto-
moses techniques. Data for anastomotic leak and reoperation rates for mechanical 
and handsewn suturing were taken from international published literature. Given 
procedure volume variability in comparable hospitals, base-case scenario assumed 
100 annual procedures with each anastomosis technique. Considered complications 
were anastomotic leak (requiring readmission) and reoperation due to fistuliza-
tion and anastomotic stricture. Stapler, cutter and traditional suture utilization 
patterns were based on expert opinions, while their unitary costs were provided 
by internal resources. Inflation-adjusted DRGs from IMSS´s second level hospitals 
were used as hospitalization, readmission and reoperation costs. Results are shown 
in 2015-adjusted USD; considered time horizon was < 1 year, thus no discount rate 
for costs was necessary. Results: Stapled colorectal anastomoses resulted in a 
significant reduction in anastomotic leaks and reoperations compared to handsewn 
technique. Net potential savings due to avoided readmissions and reoperations with 
mechanical stapler accounted for $32,422 and $197,992 respectively; net saving per 
patient was $1,784. cOnclusiOns: The use of stapling devices to perform ileocolic 
anastomosis can yield potential clinical and economic benefits due to the reduction 
of readmission and reoperation rates. Local public healthcare institutions should 
consider the adoption of mechanical stapling techniques in colorectal surgery as it 
appears to be a cost saving alternative.
appropriate care when the blood-based EGFR mutation testing was used as an alter-
native test to tissue-based EGFR mutation testing alone (93% vs 90%, respectively). 
As a result of increased diagnostic yield, there was a 23% decrease in cost per 
NSCLC patient per month compared to tissue-based testing alone ($1,665 vs $1,265). 
Costs per NSCLC patient per month are similar when blood-based testing is used 
in place of CT scan for ongoing monitoring of tumor progression. cOnclusiOns: 
The blood-based cobas® EGFR Mutation Test has advantages for patient outcomes 
when performed as an alternative test to tissue-based testing when tissue sample 
is not available or when used as an ongoing monitoring tool for tumor progres-
sion. By correctly identifying more patients for proper treatment, the blood-based 
test represents a good alternative to tissue-based testing for identification of EGFR 
mutations in locally advanced or metastatic NSCLC patients.
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A MoDel to exPlore the PotentiAl BuDget iMPAct of A novel 
screening tool for the Detection of suBclinicAl rejection AMong 
kiDney trAnsPlAnt PAtients
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Objectives: Advances in molecular diagnostics for the detection of disease can pro-
vide opportunities for healthcare providers to intervene earlier and subsequently, 
improve outcomes. Payers are increasingly focused on assessing the cost and over-
all value of such tools. The kSORT assay is a non-invasive test that can be used 
as a screening tool to detect subclinical rejection (SCR) among kidney transplant 
patients. The current standard of care may consist of routine screening for clini-
cal acute rejection (AR) or the use of invasive surveillance biopsies to detect SCR 
through histologic diagnosis. Preliminary data show that the k-SORT assay performs 
as well as and potentially superior to biopsies for the detection of SCR and prediction 
of AR. The objective of this analysis is to evaluate the potential budget impact of 
the kSORT assay from a commercial payer perspective using a set of conservative 
assumptions. MethOds: A 2-year Markov model incorporating SCR, AR, and graft 
failure was developed to evaluate the budget impact from a U.S. commercial payer 
perspective of the k-SORT assay among patients with incident kidney transplants. 
Probabilities for progression were obtained by calibrating the values to correspond 
with reported prevalence rates of SCR and incidence rates of AR from published 
registry data. Costs were obtained through the peer-reviewed literature and sensitiv-
ity analyses were performed. Results: Across a set of conservative assumptions, 
use of the kSORT assay may have a minimal budget impact (< $0.05) PMPM across 
most scenarios. Key value drivers include the frequency of monitoring, costs of 
the assay, and concurrent use of protocol biopsies with the assay. cOnclusiOns: 
The use of k-SORT to detect SCR is likely to produce a minimal budget impact for 
commercial payers. Additional studies demonstrating the clinical performance of 
the assay compared to biopsies can help to provide further insight into the clinical 
and economic benefits.
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Objectives: Hypoglycemic events (HEs) are important acute complications in 
patients with diabetes mellitus, especially insulin-treated. Severe HEs (sHEs) cause 
high treatment costs and have a major impact on patients’ quality of life. A newly 
available, innovative blood glucose measurement device (IBGMD), using a technology 
identifying patterns of low blood glucose and alerting the patient about a potential 
sHE (“pattern alert technology”, PAT), is studied to determine (i) the number of avoid-
able sHEs through deployment of IBGMD using PAT, compared to a conventional 
blood glucose measurement device (CBGMD), (ii) the IBGMD net cost, and (iii) its 
impact on overall management costs. MethOds: Values attached to epidemiologic, 
cost and behavioral input variables were taken from scientific literature and authori-
tative sources. A decision-analytic, one-year model comparing direct costs (payer 
perspective) and sHE outcomes between IBGMD and CBGMD was developed, and 
budget impact and cost-effectiveness calculations were performed, reflecting the 
US insulin-treated diabetic population. Results: On an overall population level, 
in the base-case scenario (sHE incidence 8.99%, PAT compliance 90%), usage of the 
IBGMD could lead to an extra 92,181 avoided sHEs annually, compared to a CBGMD. 
Assuming price parity of test strips across both devices ($0.21/strip at Medicare 
price $10.40 per 50-unit pack), its implementation is cost-neutral. At an average 
treatment cost of $7,598 per single sHE, this would lead to overall net cost savings 
of over $700 million per year. In alternative scenarios, achievable savings range 
from $103.7 million to nearly $6.7 billion per year. In terms of incremental cost-
effectiveness, IBGMD is considered dominant, as it features higher effectiveness 
(extra sHEs avoided) at lower overall costs compared to a CBGMD. cOnclusiOns: 
An innovative blood glucose measurement device with pattern alert technology 
can avoid a sizeable number of sHEs and may lead to considerable cost savings, if 
implemented widely in the target population.
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Objectives: Intra-articular injection of hyaluronic acid (HA) for knee osteoarthritis 
(OA) effectively reduces pain and delays total knee replacement (TKR) surgery; how-
ever, little is known about relative differences in clinical and cost outcomes among 
different HA products. We aimed to compare disease-specific costs and risk of TKR 
